KAMPALA — The boxes stacked past the loading dock at Africa CDC’s Eastern Regional Coordinating Centre in early June did not carry the insignia of Médecins Sans Frontières or the World Health Organization. They carried India’s tricolor emblem: 43 tonnes of diagnostic kits, protective gowns and sample-transport coolers that had left New Delhi aboard an Indian Air Force C-17 Globemaster III two days earlier, bound for a virus outbreak that had already blown through one international deadline and was about to test another.
The World Health Organization’s latest situation report, dated July 3, puts the combined case count across the Democratic Republic of Congo, Uganda and France at 1,481, with 454 deaths. That is 54 more confirmed infections and 14 more deaths than the previous update, a reminder that six weeks after the outbreak was declared a public health emergency of international concern, the Bundibugyo strain of Ebola is still finding people to infect.
Ituri Province in northeastern Congo remains the epicenter, accounting for the bulk of the country’s 1,460 confirmed cases and 452 deaths. Uganda has reported 20 cases and two deaths since the virus crossed the border in late May. A French physician who had been working a humanitarian rotation in Congo became the first confirmed case on European soil after flying home in late June, when the outbreak stood at barely 1,100 infections.
None of that explains why an Indian Air Force transport plane landed in Kampala carrying oxygen concentrators and infection-control gowns. The answer traces back to a request the African Union Commission sent to New Delhi in the outbreak’s first week, asking not for money but for equipment Africa CDC’s own procurement pipeline could not move fast enough: sample transport kits, diagnostic monitors and protective gear that frontline health workers were already running short of in Ituri’s overwhelmed treatment units.
India answered twice. A first consignment of roughly 2.5 tonnes reached Kampala on May 24, ten days after WHO’s emergency declaration. A second and far larger shipment, the 43 tonnes that filled the C-17’s cargo hold on June 2, followed once Africa CDC sent New Delhi a more detailed list of what its Eastern Regional Coordinating Centre actually needed. India’s High Commissioner to Uganda, Upender Singh Rawat, handed the consignment over in person.
India’s Ministry of External Affairs spokesperson Randhir Jaiswal, asked about the shipment at a briefing in New Delhi, kept his description almost deliberately modest, saying India had sent supplies to Africa CDC and would keep providing updates as the response continued. There was no dollar figure attached, no press conference in Kampala, no line in a G20 communique. The aid moved through a regional coordinating office most readers outside the public-health field have never heard of.
That quiet is notable against how loud the funding gap has become. On June 5, WHO and Africa CDC launched a joint continental plan seeking $518 million to fund surveillance, laboratory testing, clinical care and community engagement through November, an unusually large ask for a virus strain that has never had a licensed vaccine or an approved treatment. Six months of Bundibugyo containment, in other words, works out to roughly $350,000 for every confirmed case recorded so far, and neither agency has said publicly how much of that total has actually been pledged.
Against that backdrop, in-kind shipments like India’s matter less for their sticker price than for their timing. Diagnostic monitors and sample-transport coolers sitting in a warehouse do a treatment unit no good if they arrive after the surge that needed them has passed. Uganda’s Ministry of Health has held its case count at 20 since June 21, with no new infections reported in the eleven days since, the first sustained pause the outbreak has produced since transmission first crossed the border from Congo in late May. Ituri Province has shown no equivalent slowdown.
The treatment gap underneath all of this remains unresolved. WHO enrolled its first patients in the PARTNERS trial in Ituri in late June, testing remdesivir alongside a monoclonal antibody against a virus for which no therapeutic has ever been licensed, and results are not expected for weeks. Protective gear and diagnostic kits can slow how fast Bundibugyo spreads through a household or a ward. They cannot cure the people already infected, and until the trial reports back, clinicians in Ituri are still treating this outbreak with supportive care, rehydration and whatever protective equipment reaches them in time.
Thirteen African Union member states, including Kenya, Rwanda, Burundi, Tanzania and South Sudan, have been meeting under Africa CDC’s coordination in Kampala as countries considered at elevated risk of cross-border spread. Bundibugyo virus, the rarest of the orthoebolaviruses, has never had a licensed vaccine, part of why WHO’s emergency committee has been reluctant to call the outbreak contained even as Uganda’s numbers hold steady. The strain killed nurses and emptied homes across Ituri in the outbreak’s earliest weeks, when the case count stood in the dozens rather than the thousands.
What is not yet clear, and what neither Africa CDC nor India’s Ministry of External Affairs has addressed publicly, is how much of the 43-tonne shipment has actually reached treatment units in Ituri, as opposed to sitting in the regional depot in Kampala that received it. Aid delivered to a coordinating center and aid distributed into a nurse’s hands in a rural health post are not the same event, and the gap between the two has undone international response efforts in past Ebola outbreaks. For now, the tricolor on the crates is confirmed. What happens to the crates after that is not.
